Psychedelic Research and Access in
Taiwan
Blossom currently tracks 8 psychedelic clinical trials connected to Taiwan. The country page also links to 1 stakeholder, giving the page ecosystem context beyond registered studies.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inTaiwan.
- 1
Blossom tracks 8 psychedelic clinical trials connected to Taiwan, with none currently marked active.
- 2
Visible trial compounds include Esketamine and Ketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 1 stakeholder in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research and Access Snapshot
Blossom currently tracks 8 psychedelic clinical trials connected to Taiwan.
- Active trials
- 0
- Total trials
- 8
- Stakeholders
- 1
- Events
- 0
None marked active
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(5)
- Ketamine(3)
Top Study Topics
- Treatment-Resistant Depression (TRD)(6)
- Major Depressive Disorder (MDD)(2)
Medical Access
Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non-medical possession and diversion are criminalized; dedicated esketamine...
Research Landscape
What the 8 registered trials connected to Taiwan look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 8 Taiwan trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Regulatory Status
The linked medical access and reimbursement guide summarises Taiwan as "Medical Only (Private)". Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non-medical possession and diversion are criminalized; dedicated esketamine (Spravato®) regulatory status in Taiwan is not documented in public TFDA approvals as of Feb 20, 2026.
Country Details
- Region
- Asia
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Taiwan.
Open scorecard →Psychedelic Stakeholders in Taiwan
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Taiwan.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Taiwan.